Sugi Predict

Sugi Predict / Compounds / SCHEMBL499450

SCHEMBL499450

SCHEMBL499450

C[C@H](N)C(=O)OC(=O)[C@@H]1CCCN1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NOS2 P35228 2/20 0.39
▸ NOS3 P29474 1/20 0.39
▸ NOS1 P29475 1/20 0.39
▸ PRCP P42785 1/20 0.35
▸ DPP4 P27487 5/20 0.34
▸ DPP7 Q9UHL4 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ DPP8 Q6V1X1 2/20 0.33
▸ DPP9 Q86TI2 2/20 0.33
▸ SCN4A P35499 1/20 0.33
▸ GLI1 P08151 1/20 0.33
▸ TLR2 O60603 2/20 0.33
▸ ELANE P08246 1/20 0.33
▸ FAP Q12884 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15210886 1.00 NOS2 (0.39) NOS2NOS3NOS1PRCPDPP4
SCHEMBL27646576 1.00 NOS2 (0.39) NOS2NOS3NOS1PRCPDPP4
SCHEMBL28994810 0.89 NOS2 (0.38) NOS2NOS3NOS1PRCPDPP4
SCHEMBL2543576 0.89 NOS2 (0.38) NOS2NOS3NOS1PRCPDPP4
SCHEMBL9592134 0.86 NOS2 (0.37) NOS2NOS3NOS1PRCPDPP4
SCHEMBL3236621 0.86 NOS2 (0.36) NOS2NOS3NOS1PRCPDPP4
SCHEMBL28695544 0.85 NOS2 (0.36) NOS2NOS3NOS1PRCPDPP4
Hydrochloric Acid SCHEMBL6026726 0.85 NOS2 (0.36) NOS2NOS3NOS1PRCPDPP4
SCHEMBL1740647 0.85 NOS2 (0.36) NOS2NOS3NOS1PRCPDPP4
SCHEMBL11559604 0.84 NOS2 (0.41) NOS2NOS3NOS1PRCPDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 951 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250345420-A1 CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION UNIV CORNELL (US) 2025-11-13 — — US claimed
EP-4531917-A1 CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION Cornell University (US) 2025-04-09 — — EP claimed
CN-119677538-A Cancer immunotherapy for promotion of hyperacute rejection 康奈尔大学 2025-03-21 — — CN claimed
US-20250002851-A1 METHODS OF PREPARING T CELLS FOR T CELL THERAPY KITE PHARMA, INC. 2025-01-02 — — US claimed
EP-4419559-A1 SIGNALING DOMAINS FOR CHIMERIC ANTIGEN RECEPTORS Kite Pharma, Inc. (US) 2024-08-28 — — EP claimed
US-20240269148-A1 Enhancement of Anti-Angiogenic Cancer Immunotherapy by Abortogenic Agents THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (US) 2024-08-15 — — US claimed
US-12018080-B2 Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway THE BROAD INSTITUTE, INC. (US) 2024-06-25 — — US claimed
CN-118103403-A Signal transduction domains of chimeric antigen receptors 凯德药业股份有限公司 2024-05-28 — — CN claimed
US-20240100160-A1 ENHANCEMENT OF T CELL HOMING TO TUMORS THROUGH AUGMENTATION OF CHEMOKINE RESPONSIVENESS AND ACTIVATION DEPENDENT CHEMOKINE SECRETION Regen BioPharma, Inc. (US) 2024-03-28 — — US claimed
US-20240009243-A1 METHODS OF PREPARING T CELLS FOR T CELL THERAPY KITE PHARMA INC (US) 2024-01-11 — — US claimed
WO-2010065876-A2 METHODS AND COMPOSITIONS RELATED TO TH-1 DENDRITIC CELLS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-06-10 — — WO claimed
US-20100015070-A1 USE OF NATURAL, RECOMBINANT AND SYNTHETIC RESILINS IN COSMETICS BASF SE (DE) 2010-01-21 — — US claimed
CN-101563104-A Polypeptide-nucleic acid conjugates for immunoprophylaxis or immunotherapy of neoplastic or infectious diseases UNIV JOHNS HOPKINS (US) 2009-10-21 — — CN claimed
CN-101390600-A Preparation method of seafresh flavor essence TIANJIN SHUANGXING ESSENCE & S (CN) 2009-03-25 — — CN claimed
EP-1986698-A2 POLYPEPTIDE-NUCLEIC ACID CONJUGATE FOR IMMUNOPROPHYLAXIS OR IMMUNOTHERAPY FOR NEOPLASTIC OR INFECTIOUS DISORDERS The Johns Hopkins University (US) 2008-11-05 — — EP claimed
US-20070212337-A1 Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders THE JOHNS HOPKINS UNIVERSITY (US) 2007-09-13 — — US claimed
WO-2007089871-A2 POLYPEPTIDE-NUCLEIC ACID CONJUGATE FOR IMMUNOPROPHYLAXIS OR IMMUNOTHERAPY FOR NEOPLASTIC OR INFECTIOUS DISORDERS THE JOHNS HOPKINS UNIVERSITY (US) 2007-08-09 — — WO claimed
US-20050147621-A1 Use of bacterial 5' untranslated regions for nucleic acid expression PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2005-07-07 — — US claimed
US-20040057958-A1 Immunogenicity-enhancing carriers and compositions thereof and methods of using the same CELL THERAPEUTICS, INC. 2004-03-25 — — US claimed
CN-87106235-A Treat atherosclerotic method and base composition — 1988-05-18 — — CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002851-A1 METHODS OF PREPARING T CELLS FOR T CELL THERAPY IL15, CD4, IL2 NOS2 2101/4885NOS3 2901/4885NOS1 2436/4885
US-12018080-B2 Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway KLRK1, CD47, FCGR3B NOS2 2459/4885NOS3 3094/4885NOS1 2057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.